tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in cml patients

Clicks: 264
ID: 250765
2014
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract

At present, introduction of target therapy to chronic myelogenous leukemia (CML) treatment made CML not life-limiting disorder. The main condition of treatment efficacy is its continuity. The most common causes of dose reduction and CML therapy interruption is hematologic toxicities such as neutropenia and thrombocytopenia. The adverse events correction in these circumstances is vital. Recommendations for neutropenia and thrombocytopenia correction are proposed in this article. The basement and results of the use of granulocyte colony stimulating factor (G-CSF) and thrombopoietine receptor agonist for hematologic toxicities correction with clinical case are presented.

Reference Key
shuvaev2014onkogematologityrosine Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;V. A. Shuvaev;M. S. Fominykh;I. S. Martynkevich;V. Y. Udaleva;N. A. Potikhonova;M. N. Zenina;K. M. Abdulkadyrov
Journal basic and clinical neuroscience
Year 2014
DOI
DOI not found
URL
http://oncohematology.abvpress.ru/index.php/ongm/article/view/12
Keywords
imatinib tyrosine kinase inhibitors neutropenia dasatinib romiplostimdiseases of the blood and blood-forming organs

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.